Since the mid-1950s the pharmaceutical industry has developed a number of chemicals, including phencyclidine, ketamine and related arylcyclohexylamines (PCE and TCP), dizocilpine , N-allylnormetazocine [ NANM, (&plusmn;)SKF-10,047], etoxadrol, dioxadrol and its enantiomers dexoxadrol and levoxadrol, which produce a constellation of unusual behavioral effects in animals and man. The compounds best studied in humans are phencyclidine and ketamine. They produce a remarkable dose-dependent dissociation of awareness. All of these substances are now known to be non-competitive antagonists of NMDA receptors of glutamic acid. They act in the NMDA receptor ion channel. One can conclude, on the basis of the effects observed with these agents, that glutamic acid and related excitatory amino acids are extremely important in the maintenance of human awareness.
, and later as a chemical model of sensory deprivation (Meyer, Greifenstein and DeVault, 1959) and schizophrenia (Luby et al., 1959 (Luby et al., , 1962 Cohen et al., 1959) well before its primary mechanism of action was determined to be that of a non-competitive NMDA receptor antagonist.
The history of phencyclidine and related arylcyclohexylamines was described by a number of the early investigators. It has been documented from the point of view of a medicinal chemist (Maddox, 1981) , neuropharmacologist (Chen, 1981; McCarthy, 1981) and a psychiatrist (Luby, 1981) . Domino and Luby (1981) Luby, 1981 better model than the others. Luby et al. (1959) and Cohen et al. (1959) (Lear et al., 1959; Scholler, Thies and Wiemers, 1960) .
More recently, Javitt and Zukin (1991) emphasized that a number of positive and negative symptoms of schizophrenia can be induced in normal volunteers or drug abusers with phencyclidine. Carlsson and Carlsson (1990) have observed in animals interactions between glutamatergic and monoaminergic systems in the brain that have implications for schizophrenia. Fauman and Fauman (1981) and Burns and Lerner (1981) reviewed in detail the drug abuse aspects and pharmacology of phencyclidine in man. Table 2 lists the dose-effect relationships of phencyclidine in normal or drug abuse subjects as reported by Burns and Lerner (1981) . It McCarthy (1981) . Corssen (1990) and Dundee (1990a,b) have reviewed the Dizocilpine When MK-801 was first described by Clineschmidt et al. (1982a-c) (1976) described the canine delirium induced with ( ± )SKF-10,047. They suggested that ( ± )SKF-10,047 is a ligand for a sigma 'opioid' receptor. We now know that ( -)SKF-10,047 has opioid properties and that in low concentrations ( + )SKF-10,047 is a ligand for a nonopioid sigma receptor and in very high concentrations a ligand for the PCP site in the ion channel of the NMDA receptor. Musacchio (1990) reviewed the relationship between the psychotomimetic effects of opiates and the sigma receptor. He concluded that the dysphoric and psychotomimetic effects of opiates reside with the ( -) and not the (+) enantiomers. Naloxone does not antagonize the effects of phencyclidine and ( ± )SKF-10,047 in dogs (Vaupel, 1983) . Vaupel has also shown that ( + )SKF-10,047 produces typical phencyclidine-like effects in dogs, while ( -)SKF-10,047 is less potent. The term sigma receptor has taken on a new meaning. A very large literature exists on this subject (see symposia volumes by Domino and Kamenka, 1988; Kamenka and Domino, 1992) . Keats and Telford (1964) found that (±)SKF-10,047 is dysphoric in humans. Whether ( + )SKF-10,047 is more dysphoric than ( -)SKF-10,047 in humans is unknown. The effects of both agents given separately on human awareness have yet to be determined. In animal behavioral experiments ( + )SKF-10,047 is phencyclidinelike (Brady, Balster and May, 1982; Koek and Woods, 1988a,b) and is a NMDA antagonist (Largent, Gundlach and Schneider, 1986 (Frederickson, Longnecker and Allen, 1976; Wilson et al., 1970 Wilson et al., , 1973 . Dioxadrol, a related compound, has a pharmacology similar to etoxadrol. The ( + ) enantiomer of dioxadrol is dexoxadrol and the ( -) enantiomer is levoxadrol. Jasinski, Martin and Sappira (1968) , Lasagna and Pearson (1965) and Simopoulos et al. (1970) reported analgesic and psychotomimetic effects with dexoxadrol in humans that are similar to those reported with phencyclidine. Hampton et al. (1982) 
